Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant - Archive ouverte HAL Access content directly
Journal Articles Pharmaceutics Year : 2022

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8) , (9, 10) , (11) , (12)
1
2
3
4
5
6
7
8
9
10
11
12

Abstract

To assess anatomical and functional outcomes after switching from dexamethasone implant (DEXi) to fluocinolone acetonide implant (FAci) in 113 diabetic macular edema eyes, a multicentric retrospective observational study was conducted. Seventy-five eyes (73.5%) were switched 1–8 weeks after their last DEXi. The mean best-corrected visual acuity improved to 59.8 letters at month 4 and remained stable during the follow-up. The mean central macular thickness (CMT) significantly decreased during the follow-up, with a minimum of 320.9 μm at month 3. The baseline CMT was higher in eyes that received the last DEXi >8 weeks versus <8 weeks before the first FAci (p < 0.021). After FAci injection, additional treatments were needed in 37 (32.7%) eyes. A longer diabetes duration (p = 0.009), a longer time between the last DEXi and the first FAci (p = 0.035), and a high baseline CMT (p = 0.003) were risk factors for additional treatments. The mean intraocular pressure was <19 mmHg at all timepoints, with no difference between eyes receiving the last DEXi ≤8 weeks or >8 weeks before the switch. Switching from DEXi to FAci in DME is effective and safe. A short time between the last DEXi and the first FAci reduced CMT fluctuations and the need for early additional treatments.
Fichier principal
Vignette du fichier
baillif_2022_vol14_2391_pharmaceutics.pdf (8.06 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY - Attribution

Dates and versions

hal-03854968 , version 1 (16-11-2022)

Licence

Attribution - CC BY 4.0

Identifiers

Cite

Stéphanie Baillif, Pascal Staccini, Michel Weber, Marie-Noëlle Delyfer, Yannick Le Mer, et al.. Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant. Pharmaceutics, 2022, 14 (11), pp.2391. ⟨10.3390/pharmaceutics14112391⟩. ⟨hal-03854968⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More